Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
Pfizer (PFE) has initiated a new Phase 1 study for its experimental drug PF-07328948 to understand its pharmacokinetics in healthy adult men. The study, which is not yet recruiting, will evaluate oral liquid and tablet forms, including a radiolabeled version, to determine absorption, distribution, metabolism, and excretion. This early-stage research supports Pfizer's long-term pipeline development but is not expected to be a near-term catalyst for the company's stock.
Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035 - Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas
The global Messenger RNA (mRNA) market is set to expand significantly, reaching an estimated $20.99 billion by 2035, driven by its application in treating and preventing diseases, particularly in vaccines and therapeutics. This growth is bolstered by strong clinical validation, rapid development timelines, substantial investments, and advancements in delivery technologies. North America is a leading region due to its regulatory framework and manufacturing capabilities, with key players like Moderna and Pfizer continuing to innovate in this space.
RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating
RBC Capital Markets has raised its price target for Moderna (MRNA) to $35 from $30, while reiterating a "Sector Perform" rating on the stock. This adjustment reflects a revised outlook from the analyst firm. The article also notes other recent analyst rating changes for Moderna from Barclays, Deutsche Bank, and Berenberg.
Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma
The Oncolytic Virus Therapies market is projected for strong growth through 2034, driven by increasing cancer prevalence and advancements in biotechnology. Key companies like CG Oncology, Imugene, and Amgen are developing various therapies, with several receiving FDA designations and progressing through clinical trials. The report highlights RP1 (Replimune Inc.) for advanced melanoma and discusses market drivers and barriers for this emerging cancer treatment approach.
Mesoblast’s Ryoncil Achieves US$30.3 Million in Net Sales for March Quarter
Mesoblast Limited announced strong sales results for its product Ryoncil, with net sales reaching US$30.3 million for the quarter ending March 31, 2026. This performance contributed to nearly US$100 million in revenue since Ryoncil's launch, strengthening the company's balance sheet. Mesoblast will host an R&D Day on April 8, 2026, to discuss its growth strategy for Ryoncil and its pipeline, emphasizing the product's significance as the first FDA-approved mesenchymal stromal cell product.
Spikevax Vaccine: Key Role in mRNA COVID Protection
The article highlights Spikevax, Moderna's mRNA COVID-19 vaccine, and its crucial role in preventing severe illness from SARS-CoV-2. It details the vaccine's mRNA technology, high efficacy, adaptability to new variants, and global distribution. Furthermore, the piece discusses Spikevax's market relevance, future developments in mRNA vaccine technology, and Moderna's contribution to public health.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Moderna announced it will present late-breaking oral presentations on revaccination data for its investigational seasonal influenza vaccine (mRNA-1010) and its RSV vaccine (mRESVIA) at the 2026 ESCMID Global Congress. The data indicates that sequential administration of mRNA-1010 showed similar immunogenicity to initial vaccination and no new safety concerns, while mRESVIA revaccination after a primary protein-based vaccine was well-tolerated and suggested protection comparable to primary dose levels. Moderna expects the first potential approvals for mRNA-1010 in 2026.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Moderna will present late-breaking revaccination data for its investigational seasonal influenza vaccine (mRNA-1010) and its RSV vaccine (mRESVIA) at the ESCMID Global Congress in April 2026. The data for mRNA-1010 shows similar immunogenicity and no new safety concerns after sequential administration in older adults. For mRESVIA, interim results suggest revaccination can restore protection comparable to primary dose levels.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
Moderna will present late-breaking revaccination data for its investigational seasonal influenza vaccine, mRNA-1010, and its RSV vaccine, mRESVIA, at the 2026 ESCMID Global Congress. The data will cover the safety and immunogenicity of mRNA-1010 in older adults after prior seasonal influenza vaccination and interim results for mRESVIA revaccination after a primary protein-based vaccine. Moderna expects potential approvals for mRNA-1010 in 2026 and will present additional research across various infectious diseases.
Moderna (MRNA) CFO vests RSUs, 703 shares withheld for tax
Moderna's CFO, James M. Mock, reported a routine equity compensation activity where 1,453 restricted stock units converted into common shares on April 2, 2026. To cover tax withholding obligations, 703 common shares were withheld at $50.03 per share, rather than being sold. As a result, Mock's direct holdings of common shares increased to 57,748, in addition to 2,906 restricted stock units.
PTCT Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of recent news and events related to PTCT stock, including appointments to the board, stock option approvals, and market analysis that could affect biotech stocks. It also details major market events like KKR's planned sale of CoolIT Systems, Dr. Vinay Prasad's departure from a regulatory agency impacting drug approvals, Plug Power's hydrogen offering, and Prudential's unauthorized data removal incident. Additionally, the article mentions activist investor Starboard Value's stake in Lamb Weston.
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes
Jim Cramer highlighted Moderna's significant rally, with the stock up 72% in the first quarter, making it the sixth-best performer in the S&P 500. He attributed this breakout to the company settling key lawsuits, the FDA reviewing its new flu vaccine, and the impending departure of a vaccine skeptic from the FDA. Cramer suggested these factors are very positive for Moderna, a company primarily focused on vaccines.
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes
Jim Cramer highlighted Moderna's strong performance in the first quarter, with the stock up 72%, making it the sixth best performer in the S&P 500. He attributed this rally to the settlement of key lawsuits, FDA review of their new flu vaccine, and the upcoming departure of a vaccine-skeptic leader from the FDA. Cramer noted that while Moderna's past success relied heavily on its COVID vaccine, the company is now making progress in other areas like flu vaccines and treatments for cancer and rare diseases.
Replimune Sees Positive Momentum Amid Strategic Developments
Replimune Group Inc. (NASDAQ: REPL) has seen its stock rise by 10.78% due to strategic developments, partnerships, and a strong cash position, despite facing significant financial challenges like negative EBITDA and net income. Analysts are cautiously optimistic about its growth potential, highlighting R&D investments and a recent strategic acquisition, while noting the need for improved operational efficiency and breakthrough innovations. The company's financial health shows robust liquidity but also a moderate debt level, making future strategic financial planning crucial for its ascent in the biotech sector.
MRNA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Moderna Inc. (MRNA) based on various indicators. It details MRNA's technical sentiment as Neutral, with 5 indicators suggesting buy and 5 indicating sell, and includes analysis of moving averages, momentum indicators like RSI and MACD, and key support and resistance levels. The stock is currently trading above its 60-day and 200-day moving averages, indicating a potentially bullish long-term trend.
Zai Lab Ltd (ADR) stock: China's biotech powerhouse eyes global gains
Zai Lab Ltd (ADR) offers North American investors exposure to China's rapidly growing biotech sector, focusing on oncology and rare diseases through innovative in-licensing partnerships. The company leverages global therapies for the vast Chinese market, utilizing an ADR structure for easy access. While presenting significant growth opportunities due to China's surging healthcare spending, investors should also consider risks like regulatory delays, competition, and geopolitical tensions.
Novavax Inc stock: Biotech innovator or fading COVID play?
Novavax Inc is navigating the post-pandemic market with its recombinant protein platform, moving beyond its COVID-19 vaccine to focus on combination vaccines and broader infectious disease applications. While analysts are divided, with a consensus "Hold" rating, the company's long-term promise lies in its innovative vaccine technology and potential partnerships. Investors should monitor clinical trial readouts, earnings, and regulatory approvals given the high risks and volatility associated with biotech stocks.
Sunshine Biopharma (NASDAQ: SBFM) 2025 revenue reaches $36.3M
Sunshine Biopharma Inc. reported increased revenues of $36.3 million in 2025, primarily driven by expanded generic drug sales in Canada through its Nora Pharma subsidiary. Despite the revenue growth, the company remains unprofitable, recording a net loss of $5.98 million as it continues to invest in its pipeline of 71 generic drugs and proprietary drug development programs for cancer and SARS coronaviruses. The company ended 2025 with $9.12 million in cash, which it anticipates will fund operations for approximately 18 months.
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro
The Multiple System Atrophy (MSA) market is projected for significant growth, from USD 44 million in 2025 to USD 1,753 million by 2034, driven by advancements in therapies from companies like Alterity Therapeutics, Ionis Pharmaceuticals, and Biohaven Pharmaceuticals. The US currently holds the largest market share, with Germany leading in EU4 and the UK. The report highlights upcoming therapies and stresses the increasing prevalence and awareness of this rare neurodegenerative disorder as key market drivers.
Moderna (MRNA) stock dips while market gains: Key facts
NULL
Moderna stock hits 52-week high at 55.22 USD
Moderna's stock recently achieved a 52-week high of $55.22, reflecting strong performance with 64% return over the past year and 105% in six months, driven by vaccine advancements and strategic partnerships. Despite current trading at $53.73, InvestingPro analysis suggests it might be overvalued. Recent developments include a significant patent dispute settlement and a positive European regulatory opinion for its flu-COVID combination vaccine.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed down 1.66% at $49.20 while the broader market saw gains or slight losses. Over the past month, Moderna's shares have fallen 13.44%, underperforming its sector and the S&P 500. Analysts expect Moderna to report earnings of -$2.03 per share and revenue of $229.96 million in its upcoming disclosure, with a current Zacks Rank of #3 (Hold).
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. announced that its drug candidate, CTIM-76, has received FDA Fast Track Designation for treating platinum-resistant ovarian cancer. CTIM-76 is a T cell engaging bispecific antibody currently in a Phase 1 clinical trial, with interim data expected in June 2026. This designation aims to accelerate the development and review of the drug, addressing an unmet medical need for patients.
Onconetix (STU:J4T1) Cyclically Adjusted Price-to-FCF : (As of Apr. 02, 2026)
This article explains the concept of Cyclically Adjusted Price-to-FCF (CAPFCF) as applied to Onconetix (STU:J4T1). It highlights that due to insufficient historical data, GuruFocus cannot calculate the CAPFCF for Onconetix. The article details what CAPFCF is, how it differs from regular Price-to-Free-Cash-Flow, and lists related financial terms.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
Shares of Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna fell after reports suggested the U.S. might impose up to 100% tariffs on imported branded and patented drugs. This potential move targets pharmaceutical companies that have not agreed to lower drug prices in the United States, prompting a significant sell-off in the sector. The article notes that stock market overreactions can create buying opportunities for high-quality stocks.
YieldMax MRNA option income strategy ETF announces weekly distribution of $0.2751
The YieldMax MRNA option income strategy ETF (MRI ) has declared a weekly distribution of $0.2751 per share. Investors keeping the fund in a taxable account for at least a month may receive some of their investment back as part of the distribution. This article is a brief announcement without further details on the ETF or its strategy.
Novavax (NASDAQ:NVAX) Shares Down 5.4% - Should You Sell?
Novavax (NVAX) shares dropped 5.4% to $7.585 on Thursday, with trading volume significantly below average, despite the company exceeding Q4 earnings expectations with an EPS of $0.11 against a consensus of -$0.66 and a 66.6% revenue increase year-over-year. Analysts have mixed ratings, leading to a "Hold" consensus with an average price target of $11.88, although some firms have raised targets to $16-$19. The company's market cap stands at $1.24 billion, and institutional investors hold 53.04% of its stock.
Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays
Barclays has increased its price target for Moderna (NASDAQ:MRNA) from $25.00 to $48.00, while maintaining an "equal weight" rating, despite this new target implying a slight downside from its previous close. Other analysts have varying ratings, leading to a MarketBeat consensus of "Reduce" with a target price of $33.87. Moderna recently beat EPS and revenue estimates but saw a 33% year-over-year revenue decline and remains unprofitable.
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
Pfizer and BioNTech have halted enrollment in a large U.S. trial for their updated COVID-19 vaccine due to slow recruitment of healthy adults aged 50-64, preventing the generation of relevant post-marketing data. Moderna is reportedly facing similar issues with its own vaccine trial in the same age group, which follows new FDA requirements for placebo-controlled data. The challenges highlight difficulties in clinical trial enrollment and a potential dip in interest in COVID-19 vaccines in the U.S. market.
HC Wainwright Issues Negative Estimate for BioNTech Earnings
HC Wainwright has lowered its Q1 2026 EPS estimate for BioNTech to ($2.41) from ($2.27) and forecasts a full-year 2026 EPS of ($4.57), while maintaining a "Buy" rating and a $130 price target. This follows similar price target reductions by other firms like BMO, Citigroup, and Morgan Stanley. Despite the adjusted estimates, the consensus rating for BioNTech remains a "Moderate Buy" with an average price target of $133.07, and institutional investors have recently increased their holdings in the company.
Evotec SE Stock: Horizon Restructuring Plan Sets Stage for 2026 Turnaround Amid Upcoming Earnings
Evotec SE is approaching its Q4 and full-year 2025 earnings release on April 8, 2026, as investors closely monitor the progress of its Horizon restructuring plan. The plan aims for €75 million in cost savings by 2027 despite €100 million in restructuring costs, with growth in its biologics segment expected to offset challenges in discovery. The company expects 2026 to be a transitional year with group revenue between €700-€780 million and adjusted EBITDA from €0-€40 million, targeting over 20% EBITDA margins by 2028.
NuCana plc Stock: Prodrug Technology Platform Targets Oncology Challenges for Long-Term Investor Value
NuCana plc, a clinical-stage biopharmaceutical company, utilizes its proprietary ProTide technology to enhance the delivery and efficacy of nucleoside analog cancer drugs, targeting unmet medical needs in oncology. The company's pipeline includes Nadacomotide (NUC-3373) for colorectal cancer and Acelarin (NUC-1031) for broader solid tumor applications, with earlier-stage candidates also in development. North American investors can access NuCana shares (NCNA) on NASDAQ, offering exposure to a company with a focused development strategy in the growing oncology market, though trial risks and funding remain key watchpoints.
Allogene Therapeutics Stock Gains Momentum from Sector Tailwinds ()
Allogene Therapeutics is experiencing a surge in stock value due to a positive shift in the biotechnology sector, driven by strategic acquisitions and licensing deals. The cell therapy specialist's clinical pipeline is attracting institutional investors, pushing its stock close to its yearly peak with an approximately 96% gain since the start of the year. Future growth hinges on concrete data readouts from its research pipeline and further industry consolidation.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) saw a 12.6% jump in its stock price, attributed to a positive opinion from the European Medicines Agency regarding the expansion of Imcivree's marketing authorization. Despite this rally, the company faces a 2% lower consensus EPS estimate for the upcoming quarter, raising questions about sustained strength. The stock currently holds a Zacks Rank #3 (Hold).
Pfizer, BioNTech to pause COVID vaccine study due to low enrollment
Pfizer and BioNTech are halting a post-marketing study for their COVID-19 vaccine due to low enrollment and a slow season of COVID cases, which impacted data collection. The study was intended to assess the vaccine's effectiveness against a placebo in adults aged 50-64. The companies confirmed that the decision is not related to safety concerns but rather the inability to gather relevant data for their FDA post-marketing commitment.
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA
This article compiles various trading ideas and technical analyses for Moderna (4MRNA) from multiple contributors on TradingView, covering both bullish and bearish perspectives. Analysts discuss potential price targets, chart patterns like head and shoulders, cup and handle, and flags, along with technical indicators and fundamental catalysts such as mRNA vaccine trials. The ideas range from short-term plays based on daily movements to longer-term outlooks, with a strong emphasis on risk management and individual due diligence.
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracting, motivating, and retaining talent and aligns with its pay-for-performance compensation philosophy.
Moderna, Inc. Trade Ideas — BSESOF:0QF
This article compiles various trade ideas and technical analyses for Moderna, Inc. (0QF on BSESOF) from different traders on TradingView. The ideas range from bullish and bearish short-term strategies, pattern analysis, and price target predictions, reflecting diverse perspectives on the stock's future movements. Several posts discuss Moderna's vaccine developments and market catalysts, while others focus purely on technical indicators and chart patterns.
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Pfizer and BioNTech have halted a large U.S. trial for their updated COVID-19 vaccine in healthy adults aged 50 to 64 due to low enrollment, not safety concerns. This decision comes amidst stricter FDA trial requirements and weak U.S. demand for vaccines, making it challenging to gather enough participants. Rival Moderna is reportedly facing similar recruitment struggles for its own study in this demographic.
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
A Belgian court has ordered Poland and Romania to take delivery of 1.9 billion euros ($2.2 billion) worth of COVID-19 vaccines from Pfizer and BioNTech. Pfizer had sued the countries three years ago after they refused to comply with contracts, citing changing pandemic conditions, the war in Ukraine, and potential abuse of dominant position by Pfizer. The court dismissed these arguments and ruled in favor of Pfizer, with Poland now ordered to take 1.3 billion euros' worth and Romania 600 million euros' worth, though Poland plans to appeal.
Moderna, Inc. Trade Ideas — BSESOF:0QF
This page compiles various trading ideas and analyses for Moderna, Inc. (0QF, BSESOF), contributed by different traders on TradingView. The ideas range from bullish predictions based on technical indicators and FDA approvals to bearish outlooks due to anticipated pullbacks or competition from other pharmaceutical companies. Several traders highlight successful past trades and offer specific entry, target, and stop-loss levels for potential long or short positions.
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
Tiziana Life Sciences announced promising preclinical data for its intranasal foralumab therapy, suggesting it could combat neuroinflammation and cognitive decline associated with aging. The therapy reduced microglia activation, increased neurogenesis in the hippocampus, and lessened cellular senescence in preclinical models. These findings reinforce the therapy's mechanism of stimulating regulatory T cells to alleviate neuroinflammation, with clinical trials currently underway for various neurological conditions.
Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating
Barclays has significantly increased its price target for Moderna (MRNA) to $48 from $25, while retaining an Equalweight rating on the stock. This adjustment comes amidst recent news and analyst activity surrounding the biotechnology company. Moderna specializes in developing therapeutics and vaccines for various diseases including cancer, infectious, autoimmune, and cardiovascular conditions.
Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund
Blackstone has successfully raised US$6.3 billion for its latest life sciences fund, BXLS VI, making it the largest private vehicle dedicated to the sector. This fund, which was oversubscribed and closed at its hard cap, is 40 percent larger than its predecessor. Blackstone will continue its strategy of funding individual drug assets in advanced clinical stages rather than taking equity stakes in companies.
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) saw its shares jump 12.6% recently, following a positive opinion from the European Medicines Agency for its drug Imcivree, expanding its potential use for hypothalamic obesity. Despite this surge, the company faces a recent 2% downward revision in its quarterly EPS estimate, suggesting potential challenges ahead. Investors should monitor RYTM closely to see if the recent stock momentum can be sustained despite the negative earnings estimate trend.
SNDX Stock News Today | Earnings, Events & Price Alerts
This page provides news and event information for SNDX stock, which is Syndax Pharmaceuticals. Recent news indicates several investment firms including DAFNA Capital and Kynam Capital have either reduced or increased their stakes in Syndax Pharmaceuticals and related companies in March 2026. The site also offers stock price details, market data, and links to financial analysis tools.
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility
Fate Therapeutics Inc is a leader in iPSC-derived therapies, focusing on oncology and autoimmune treatments, utilizing its proprietary technology for scalable manufacturing of off-the-shelf natural killer and T-cells. The company's pipeline includes lead programs like FT819 for B-cell malignancies and FT522 for autoimmune conditions, positioning it as a high-risk, high-reward opportunity for North American investors in the competitive cell therapy sector. Despite operating at a cash burn typical for clinical-stage biotechs, its strategy emphasizes allogeneic products and seeks to overcome manufacturing bottlenecks faced by larger players, with clinical milestones serving as key catalysts for share value.
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics, Inc. has successfully closed an oversubscribed private placement, raising approximately $30 million. This financing, led by Soleus Capital with participation from other new and existing investors, will be used for general corporate purposes and to accelerate the clinical development of its lead oncology asset, APR-1051. The company plans to expand the evaluation of APR-1051 in specific biomarker-defined cancer populations, including uterine serous carcinoma and platinum-resistant ovarian cancer.
ABUS Should I Buy
Arbutus Biopharma Corp (ABUS) is not recommended as a strong buy for beginner, long-term investors due to a lack of clear positive momentum, absence of significant trading signals, and unimpressive financial performance. While the company boasts strong liquidity and a significant Q4 2025 revenue increase, it faces challenges with declining net income and EPS, and an ongoing patent dispute with Moderna. Analysts from Jefferies maintain a Buy rating but acknowledge the complexities of the patent case.
Moderna, Pfizer Press to Toss Bayer’s Covid-Shot Patent Suits
Moderna, Pfizer, and BioNTech are seeking to dismiss patent lawsuits filed by Bayer, which allege that their Covid-19 vaccines infringe on a crop-based genetic-engineering patent. The defendants argue that Bayer's claims are implausible, contending that most of the asserted patent claims are limited to plant or insecticidal genes and do not apply to human mRNA technologies. They further assert that the broader remaining claims amount to a "general law of nature" and are therefore invalid.
